Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

Subscribe To Our Latest Investor News

News Highlights
April 10, 2021

Combination of copanlisib and rituximab significantly increases progression-free survival in patients with relapsed indolent non-Hodgkin's Lymphoma

READ MORE
April 6, 2021

Bayer to present new clinical data at AACR Annual Meeting 2021

READ MORE
March 23, 2021
Not intended for U.S. and UK Media

Bayer receives approval for Vitrakvi™ in Japan

READ MORE
March 12, 2021

Elections at the Annual Stockholders' Meeting on April 27, 2021

Read more
AD HOC

Discover Bayer’s Latest Ad Hoc Releases

READ MORE
Explore All
81 - 90of about 613 News
81 - 90of about 613 News
February 17, 2020
Bayer to swiftly appeal jury decision in dicamba case
READ MORE
February 13, 2020
Bayer Driving Agricultural Innovation and Sustainability with Industry-Leading Pipeline and Investment
READ MORE
February 10, 2020
Not intended for U.S. and UK Media
Bayer announces Phase III trials with new aflibercept 8mg formulation
READ MORE
January 31, 2020
Bayer Welcomes U.S. Environmental Protection Agency’s Reaffirmation that Glyphosate Is Safe to Use, Not Carcinogenic
READ MORE
January 31, 2020
Not intended for U.S. and UK Media
Bayer receives positive CHMP opinion for darolutamide as a new treatment for men with non-metastatic castration-resistant prostate cancer
READ MORE
January 30, 2020
Not intended for U.S. and UK Media – Updated results of Phase III trial show:
Darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancer
READ MORE
January 23, 2020
Not intended for U.S. and UK Media
Bayer receives approval for darolutamide in Japan
READ MORE
January 13, 2020
Not intended for U.S. and UK Media
Bayer and Daré Bioscience enter into exclusive license agreement for U.S. commercial rights to investigational hormone-free, monthly contraceptive Ovaprene®
READ MORE
December 10, 2019
Bayer to significantly step-up its sustainability efforts
READ MORE
December 10, 2019
Bayer to significantly step-up its sustainability efforts
READ MORE
81 - 90of about 613 News
81 - 90of about 613 News